Crescent Competitors
| CBIO Stock | USD 8.94 0.29 3.14% |
Crescent Biopharma vs Fluoropharma Medical Correlation
Very good diversification
The correlation between Crescent Biopharma and FPMI is -0.23 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Crescent Biopharma and FPMI in the same portfolio, assuming nothing else is changed.
Moving against Crescent Stock
| 0.71 | EQ | Equillium | PairCorr |
| 0.69 | DRTS | Alpha Tau Medical | PairCorr |
| 0.63 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.58 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.52 | CMB | Cambium Bio | PairCorr |
Crescent Biopharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Crescent Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Crescent and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Crescent Biopharma does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Crescent Stock performing well and Crescent Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Crescent Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KLDO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| IVBT | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| XENO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CALA | 21.70 | 5.87 | 0.08 | (1.50) | 20.34 | 100.00 | 280.00 | |||
| NMRD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SYVC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SNNAQ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| FPMI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Crescent Biopharma Competitive Analysis
The better you understand Crescent Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Crescent Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Crescent Biopharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Crescent Biopharma Competition Performance Charts
Five steps to successful analysis of Crescent Biopharma Competition
Crescent Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Crescent Biopharma in relation to its competition. Crescent Biopharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Crescent Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Crescent Biopharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Crescent Biopharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Crescent Biopharma position
In addition to having Crescent Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Energy Funds Thematic Idea Now
Energy Funds
Funds or Etfs investing in energy sector, natural resources, and ecology. The Energy Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Crescent Biopharma Correlation with its peers. To learn how to invest in Crescent Stock, please use our How to Invest in Crescent Biopharma guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Biotechnology sector continue expanding? Could Crescent diversify its offerings? Factors like these will boost the valuation of Crescent Biopharma. Projected growth potential of Crescent fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Crescent Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Crescent Biopharma's market price often diverges from its book value, the accounting figure shown on Crescent's balance sheet. Smart investors calculate Crescent Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Crescent Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Crescent Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Crescent Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Crescent Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.